One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary InterventionA Prespecified Subgroup Analysis of a Randomized Clinical Trial
J. J. Coughlan, MB, BCh1,2; Alp Aytekin, MD1; Shqipdona Lahu, MD1; et al Gjin Ndrepepa, MD1; Maurizio Menichelli, MD3; Katharina Mayer, MD1; Jochen Wöhrle, MD4; Isabell Bernlochner, MD5,6; Senta Gewalt, MD1; Bernhard Witzenbichler, MD7; Willibald Hochholzer, MD8; Dirk Sibbing, MD6,9; Salvatore Cassese, MD1; Dominick J. Angiolillo, MD, PhD10; Rayyan Hemetsberger, MD11; Christian Valina, MD8; Arne Müller, MD5; Sebastian Kufner, MD1; Christoph Liebetrau, MD12; Erion Xhepa, MD, PhD1; Alexander Hapfelmeier, MSc13,14; Hendrik B. Sager, MD1,6; Michael Joner, MD1,6; Massimiliano Fusaro, MD1; Gert Richardt, MD11; Karl Ludwig Laugwitz, MD5,6; Franz Josef Neumann, MD8; Heribert Schunkert, MD1,6; Stefanie Schüpke, MD1,6; Adnan Kastrati, MD1,6
doi : 10.1001/jamacardio.2021.2228
JAMA Cardiol. 2021;6(10):1121-1129
It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI).
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction
Christopher J. Rush, MB, ChB, PhD1,2; Colin Berry, MB, ChB, PhD1,2; Keith G. Oldroyd, MB, ChB, MD1,2; et al J. Paul Rocchiccioli, MB, ChB, PhD2; M. Mitchell Lindsay, MB, ChB, MD2; Rhian M. Touyz, MB, ChB, PhD1; Clare L. Murphy, MB, ChB3; Thomas J. Ford, MB, ChB, PhD1,2; Novalia Sidik, MB, ChB1,2; Margaret B. McEntegart, MB, ChB, PhD1,2; Ninian N. Lang, MB, ChB, PhD1; Pardeep S. Jhund, MB, ChB, PhD1; Ross T. Campbell, MB, ChB, PhD1; John J. V. McMurray, MB, ChB, MD1; Mark C. Petrie, MB, ChB1,2
doi : 10.1001/jamacardio.2021.1825
JAMA Cardiol. 2021;6(10):1130-1143
Coronary artery disease (CAD) and coronary microvascular dysfunction (CMD) may contribute to the pathophysiologic characteristics of heart failure with preserved ejection fraction (HFpEF). However, the prevalence of CAD and CMD have not been systematically studied.
Association of Pediatric Obstructive Sleep Apnea With Elevated Blood Pressure and Orthostatic Hypertension in Adolescence
Julio Fernandez-Mendoza, PhD1; Fan He, MS2; Susan L. Calhoun, PhD1; et al Alexandros N. Vgontzas, MD1; Duanping Liao, MD, PhD2; Edward O. Bixler, PhD1
doi : 10.1001/jamacardio.2021.2003
JAMA Cardiol. 2021;6(10):1144-1151
Although pediatric guidelines have delineated updated thresholds for elevated blood pressure (eBP) in youth and adult guidelines have recognized obstructive sleep apnea (OSA) as an established risk factor for eBP, the relative association of pediatric OSA with adolescent eBP remains unexplored.
Midlife Wealth Mobility and Long-term Cardiovascular Health
Sara Machado, PhD1; Andrew Sumarsono, MD2,3; Muthiah Vaduganathan, MD, MPH4
doi : 10.1001/jamacardio.2021.2056
JAMA Cardiol. 2021;6(10):1152-1160
The association of socioeconomic status and cardiovascular outcomes has been well described, but little is known about whether longitudinal changes in wealth are associated with cardiovascular health status.
Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing FactorsThe Multi-Ethnic Study of Atherosclerosis
Jaideep Patel, MD1,2; Vincent A. Pallazola, MD2; Ramzi Dudum, MD, MPH2; et al Philip Greenland, MD3; John W. McEvoy, MBBCh, MHS2,4; Roger S. Blumenthal, MD2; Salim S. Virani, MD, PhD5,6; Michael D. Miedema, MD, MPH7; Steven Shea, MD, MS8; Joseph Yeboah, MD, MS9; Antonio Abbate, MD, PhD1; William G. Hundley, MD1; Amy B. Karger, MD, PhD7; Michael Y. Tsai, PhD7; Vasanth Sathiyakumar, MD2; Oluseye Ogunmoroti, MD, MPH2; Mary Cushman, MD10; Nazir Savji, MD2; Kiang Liu, PhD3; Khurram Nasir, MD, MPH2,11,12,13; Michael J. Blaha, MD, MPH2; Seth S. Martin, MD, MHS2; Mahmoud Al Rifai, MD, MPH2,6
doi : 10.1001/jamacardio.2021.2321
JAMA Cardiol. 2021;6(10):1161-1170
The 2018 American Heart Association/American College of Cardiology Guideline on the Management of Blood Cholesterol recommends the use of risk-enhancing factor assessment and the selective use of coronary artery calcium (CAC) scoring to guide the allocation of statin therapy among individuals with an intermediate risk of atherosclerotic cardiovascular disease (ASCVD).
Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial InfarctionA Randomized Clinical Trial
Thomas Pilgrim, MD, MSc1; René Vollenbroich, MD, MPP1; Sarah Deckarm, MS1; et al Christoph Gräni, MD, PhD1; Stephan Dobner, MD, PhD1; Anselm W. Stark, MS1; Sophie A. Erne, MS1; Flora Babongo Bosombo, PhD2; Kady Fischer, PhD3; Stefan Stortecky, MD1; Nicole Reusser, RN1; Monika Fürholz, MD1; George C. M. Siontis, MD, PhD1; Dik Heg, PhD2; Lukas Hunziker, MD1; Stephan Windecker, MD1; Jonas Lanz, MD, MSc1
doi : 10.1001/jamacardio.2021.2247
JAMA Cardiol. 2021;6(10):1171-1176
Left ventricular remodeling following acute myocardial infarction results in progressive myocardial dysfunction and adversely affects prognosis.
Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome
Anthony Demolder, MD1; Frank Timmermans, MD, PhD2; Mattias Duytschaever, MD, PhD2; et al Laura Muiño-Mosquera, MD, PhD1,3; Julie De Backer, MD, PhD1,2
doi : 10.1001/jamacardio.2021.2312
JAMA Cardiol. 2021;6(10):1177-1186
Mitral annular disjunction (MAD) has received particular interest in patients with mitral valve prolapse, ventricular tachycardia, and sudden cardiac death. The clinical significance of MAD for patients with Marfan syndrome (MFS) remains largely unexplored.
Contemporaneous Comparison of Outcomes Among Patients Implanted With a Leadless vs Transvenous Single-Chamber Ventricular Pacemaker
Jonathan P. Piccini, MD, MHS1; Mikhael El-Chami, MD2; Kael Wherry, PhD3; et al George H. Crossley, MD4; Robert C. Kowal, MD, PhD3; Kurt Stromberg, MS3; Colleen Longacre, PhD3; Jennifer Hinnenthal, MPH3; Lindsay Bockstedt, PhD3
doi : 10.1001/jamacardio.2021.2621
JAMA Cardiol. 2021;6(10):1187-1195
The safety and efficacy of leadless VVI pacemakers have been demonstrated in multiple clinical trials, but the comparative performance of the device in a large, real-world population has not been examined.
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination
Han W. Kim, MD1,2; Elizabeth R. Jenista, PhD1,2; David C. Wendell, PhD1,2; et al Clerio F. Azevedo, MD1,2; Michael J. Campbell, MD1,3; Stephen N. Darty, BS1; Michele A. Parker, MS1,2; Raymond J. Kim, MD1,2,4
doi : 10.1001/jamacardio.2021.2828
JAMA Cardiol. 2021;6(10):1196-1201
Vaccine-associated myocarditis is an unusual entity that has been described for the smallpox vaccine, but only anecdotal case reports have been described for other vaccines. Whether COVID-19 vaccination may be linked to the occurrence of myocarditis is unknown.
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Jay Montgomery, MD1,2; Margaret Ryan, MD, MPH1,3; Renata Engler, MD4; et al Donna Hoffman, MSN1,2; Bruce McClenathan, MD1,5; Limone Collins, MD1; David Loran, DNP1,3; David Hrncir, MD1,6; Kelsie Herring, MD7; Michael Platzer, MD8; Nehkonti Adams, MD4,8; Aliye Sanou, MD8; Leslie T. Cooper Jr, MD9
doi : 10.1001/jamacardio.2021.2833
JAMA Cardiol. 2021;6(10):1202-1206
Myocarditis has been reported with COVID-19 but is not clearly recognized as a possible adverse event following COVID-19 vaccination.
Population Trends in Rates of Percutaneous Coronary Interventions, 2010 to 2017
Zaid I. Almarzooq, MBBCh1,2; Rishi K. Wadhera, MD, MPP1; Jiaman Xu, MPH1; et al Robert W. Yeh, MD, MSc1
doi : 10.1001/jamacardio.2021.2639
JAMA Cardiol. 2021;6(10):1219-1220
Imposter Syndrome
Mustafa Husaini, MD1
doi : 10.1001/jamacardio.2021.2009
JAMA Cardiol. 2021;6(10):1113-1114
Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines
David K. Shay, MD, MPH1; Tom T. Shimabukuro, MD, MPH, MBA1,2; Frank DeStefano, MD, MPH2
doi : 10.1001/jamacardio.2021.2821
JAMA Cardiol. 2021;6(10):1115-1117
Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and MyocarditisThe Vaccine Safety Surveillance System Is Working
Ann Marie Navar, MD, PhD1,2; Elizabeth McNally, MD, PhD3,4; Clyde W. Yancy, MD, MSc3,5; et al Patrick T. O’Gara, MD5,6; Robert O. Bonow, MD, MS3,7
doi : 10.1001/jamacardio.2021.2853
JAMA Cardiol. 2021;6(10):1117-1118
Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction—Common, Unrecognized, and Prevalent in Patients With or Without Epicardial CAD
Viviany R. Taqueti, MD, MPH1
doi : 10.1001/jamacardio.2021.1832
JAMA Cardiol. 2021;6(10):1118-1120
Posttraumatic Stress Disorder and Cardiovascular DiseaseState of the Science, Knowledge Gaps, and Research Opportunities
Christopher J. O’Donnell, MD, MPH1,2,3; Lisa Schwartz Longacre, PhD4; Beth E. Cohen, MD, MAS5; et al Zahi A. Fayad, PhD6,7; Charles F. Gillespie, MD, PhD8; Israel Liberzon, MD9; Gita A. Pathak, PhD10,11; Renato Polimanti, PhD10,11; Victoria Risbrough, PhD12,13; Robert J. Ursano, MD14; Richard S. Vander Heide, PhD15; Clyde W. Yancy, MD, MSc16,17; Viola Vaccarino, MD, PhD18; George Sopko, MD4; Murray B. Stein, MD, MPH12,19,20
doi : 10.1001/jamacardio.2021.2530
JAMA Cardiol. 2021;6(10):1207-1216
Posttraumatic stress disorder (PTSD) is characterized by a persistent maladaptive reaction after exposure to severe psychological trauma. Traumatic events that may precipitate PTSD include violent personal assaults, natural and human-made disasters, and exposure to military combat or warfare. There is a growing body of evidence for associations of PTSD with major risk factors for cardiovascular disease (CVD), such as hypertension and diabetes, as well as with major CVD outcomes, such as myocardial infarction and heart failure. However, it is unclear whether these associations are causal or confounded. Furthermore, the biological and behavioral mechanisms underlying these associations are poorly understood. Here, the available evidence on the association of PTSD with CVD from population, basic, and genomic research as well as from clinical and translational research are reviewed, seeking to identify major research gaps, barriers, and opportunities in knowledge acquisition and technology as well as research tools to support and accelerate critical research for near-term and longer-term translational research directions. Large-scale, well-designed prospective studies, capturing diverse and high-risk populations, are warranted that include uniform phenotyping of PTSD as well as broad assessment of biological and behavioral risk factors and CVD outcomes. Available evidence from functional brain imaging studies demonstrates that PTSD pathophysiology includes changes in specific anatomical brain regions and circuits, and studies of immune system function in individuals with PTSD suggest its association with enhanced immune inflammatory activity. However, establishment of animal models and human tissue biobanks is also warranted to elucidate the potential causal connection of PTSD-induced brain changes and/or inflammation with CVD pathophysiology. Emerging large-scale genome-wide association studies of PTSD will provide an opportunity to conduct mendelian randomization studies that test hypotheses regarding the presence, magnitude, and direction of causal associations between PTSD and CVD outcomes. By identifying research gaps in epidemiology and genomics, animal, and human translational research, opportunities to better justify and design future interventional trials are highlighted that may test whether treatment of PTSD or underlying neurobiological or immune dysregulation may improve or prevent CVD risk or outcomes.
A Woman in Her 70s With Hypotension, Diffuse ST-Elevation, Murmurs, and an Intracardiac Mass
Ayaka Ino, MD1; Shiro Nakamori, MD1; Kaoru Dohi, MD1
doi : 10.1001/jamacardio.2021.2012
JAMA Cardiol. 2021;6(10):1217-1218
A Patient in Their 30s With Dyspnea and a Spongy Heart
Shahryar G. Saba, MD1,2,3; Andrew E. Arai, MD4
doi : 10.1001/jamacardio.2021.0001
JAMA Cardiol. 2021;6(10):e210001
Myocardial Infarction and Evolocumab
Harvey D. White, DSc1; Philippe Gabriel Steg, MD2; Gregory G. Schwartz, MD, PhD3
doi : 10.1001/jamacardio.2021.1994
JAMA Cardiol. 2021;6(10):1220-1221
Myocardial Infarction and Evolocumab
Mohammad Alkhalil, DPhil1,2
doi : 10.1001/jamacardio.2021.1997
JAMA Cardiol. 2021;6(10):1221-1222
Myocardial Infarction and Evolocumab—Reply
Stephen D. Wiviott, MD1; Robert P. Giugliano, MD, SM1; Marc S. Sabatine, MD, MPH1,2
doi : 10.1001/jamacardio.2021.2000
JAMA Cardiol. 2021;6(10):1222-1223
ISAR-REACT 5 Revisited Through the Lens of a Postrandomization Subgroup
Ajay J. Kirtane, MD, SM1,2
doi : 10.1001/jamacardio.2021.2238
JAMA Cardiol. 2021;6(10):1129
Error in Corresponding Author Information
doi : 10.1001/jamacardio.2021.3251
JAMA Cardiol. 2021;6(10):1223
Errors in Table 2, Limitations, and Visual Abstract
doi : 10.1001/jamacardio.2021.3329
JAMA Cardiol. 2021;6(10):1223
